Nasopharyngeal swab

AMI Partners with LifeSign To Provide the Status COVID-19/Flu A&B Test for Upcoming Respiratory Season

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Coronaviridae, Clinical medicine, Medical tests, Medical terminology, Nasopharyngeal swab, Respiratory therapy, Rapid diagnostic test, COVID-19, Severe acute respiratory syndrome, DiaSorin, Curative

Gainesville, Aug. 03, 2021 (GLOBE NEWSWIRE) -- This years upcoming respiratory season presents new uncertainty and risk on the heels of the COVID-19 pandemic.

Key Points: 
  • Gainesville, Aug. 03, 2021 (GLOBE NEWSWIRE) -- This years upcoming respiratory season presents new uncertainty and risk on the heels of the COVID-19 pandemic.
  • said Samatha Young, Head of Global Sales at AMI .
  • The LifeSign Status COVID-19 Flu A&B rapid test is a qualitative assay for the simultaneous detection of influenza A&B antigen and SARS CoV-2 antigen from nasopharyngeal swabs obtained from patients/Flu rapid combo test on the market.
  • As a leader in rapid diagnostics, LifeSign is excited and proud to partner with AMI.

A.Menarini Diagnostics launches a new Real Time PCR kit for SARS CoV-2 detection and variant screening, CE marked.

Retrieved on: 
Thursday, July 29, 2021
Laboratory techniques, Natural sciences, Chemistry, Physical sciences, Molecular biology, Polymerase chain reaction, Biotechnology, Amplifiers, Nasopharyngeal swab, Real-time polymerase chain reaction, Severe acute respiratory syndrome coronavirus 2, Assay

FLORENCE, Italy, July 29, 2021 /PRNewswire/ -- Menarini Diagnostics, part of the Menarini Group, announced today the release of a new version of the CoronaMelt Kit launched in November 2020.

Key Points: 
  • FLORENCE, Italy, July 29, 2021 /PRNewswire/ -- Menarini Diagnostics, part of the Menarini Group, announced today the release of a new version of the CoronaMelt Kit launched in November 2020.
  • The second-generation kit, CoronaMelt VAR, will combine SARS CoV-2 viral detection with concurrent genotyping of Alpha, Beta and Gamma variants (formerly known as UK, South African and Brazilian) in an IVD certified diagnostic format validated for use on laboratory Real Time PCR instruments.
  • CoronaMelt VAR is validated for use from oro/nasopharyngeal swabs with the use of standard magnetic bead or column RNA purification solution.
  • The kit is also included in the portfolio of assays that can be fully automated on the Omnia liquid handling series.

Inventive Health: COVID-19 Detected in 20 Seconds by Ultra-rapid Mouthwash or Nasal Swab Test Using Spectral Analysis Under MHRA Approval

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Health sciences, Sarbecovirus, COVID-19, Occupational safety and health, Public health, Zoonoses, Nasopharyngeal swab, Mouthwash, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Swab

These signatures are interpreted using artificial intelligence as either positive or negative for SAR-Cov-2, the virus that causes COVID-19.

Key Points: 
  • These signatures are interpreted using artificial intelligence as either positive or negative for SAR-Cov-2, the virus that causes COVID-19.
  • Samples can be collected using either a nasopharyngeal swab or non-invasive mouthwash solution.
  • The MHRA approval process is being driven by Inventive Health and is currently focused on the nasopharyngeal swab with the mouthwash alternative following soon.
  • All pathogens such as SARS-CoV-2 have a unique high resolution digital signature that can be detected using spectral analysis.

Malaysia Permission Granted for COVID-19 Test Kit from China for Emergency Use; Homegrown Holista Colltech Receives Initial Order for 15,000 Units for Deployment

Retrieved on: 
Friday, June 18, 2021
Medicine, Branches of biology, Natural sciences, Immunologic tests, Medical tests, Nasopharyngeal swab, Respiratory therapy, Rapid antigen test

With this approval, the Company has secured an initial order for 15,000 units in Malaysia.

Key Points: 
  • With this approval, the Company has secured an initial order for 15,000 units in Malaysia.
  • MOH's Medical Devices Authority ("MDA") has granted Holista permission to import and distribute up to 45,000 units of the Hecin antigen test kit for emergency use within three months from the date of approval on 14th June 2021.
  • The clinical performance of Hecin RTK-Antigen test kit against PCR Comparator method using nasopharyngeal swabs specimens has obtained a sensitivity of 96.23% and specificity 99.07%.
  • Holista CollTech Ltd ("Holista") is a natural wellness company with the following divisions:

Biomerica’s Fast 15-Minute Easy to Use COVID-19 Antigen Test Now Available With Simple Nasal Swab

Retrieved on: 
Tuesday, May 11, 2021
Anatomy, Branches of biology, Swab, Biology, Biological specimens, Sampling, Anterior nasal, Human nose, Laboratory techniques, Nasopharyngeal swab

This simple nasal swab, which takes the sample from the front opening of the nose, is less invasive and more comfortable for patients than the deep anterior nasal swab which is typically used.

Key Points: 
  • This simple nasal swab, which takes the sample from the front opening of the nose, is less invasive and more comfortable for patients than the deep anterior nasal swab which is typically used.
  • The test is highly portable, cost effective and provides visual results negating the need for any equipment to perform or read the test.
  • Our nasal swab test is simple to use, accurate and portable.\xe2\x80\x9d\nMr.
  • A simple nasal swab is used to collect specimens from people suspected of having an active infection.

Rhinostics Exclusively Licenses Innovative Product Brands’ GrooveSwab™, a Novel Nasopharyngeal Swab Designed to Improve Assay Results for COVID-19 and Respiratory Pathogen Testing

Retrieved on: 
Tuesday, May 11, 2021
Science, Other Science, Practice Management, Research, Medical Supplies, Health, Medical devices, Clinical trials, Laboratory techniques, Natural sciences, Chemistry, Physical sciences, Nasopharyngeal swab, Respiratory therapy, Swab, COVID-19, Assay

b"Rhinostics announced that it has exclusively licensed a novel nasopharyngeal swab from Innovative Product Brands, Inc. (IPB) to bring to the clinical laboratory market.

Key Points: 
  • b"Rhinostics announced that it has exclusively licensed a novel nasopharyngeal swab from Innovative Product Brands, Inc. (IPB) to bring to the clinical laboratory market.
  • IPB developed the swab to bring creative solutions to bear on the challenges facing laboratories and supply chains during the COVID-19 pandemic.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210511005010/en/\nRhinostics' GrooveSwab\xe2\x84\xa2 nasopharyngeal swab brings comfortable collection, dry transport, sample concentration and better assay performance to COVID-19 assays.\n\xe2\x80\x9cWe are excited to license our GrooveSwab\xe2\x84\xa2 nasopharyngeal swab to Rhinostics to take to market.
  • The RHINOstic product is registered as Class I exempt medical device with the FDA and is available for purchase.

Global COVID-19 Sample Collection Kits Market Report 2021-2028: Organizations Across the Globe are Developing Innovative Products for Sample Collection

Retrieved on: 
Thursday, May 6, 2021
Medicine, Infectious diseases, Medical specialties, COVID-19 testing, Nasopharyngeal swab, COVID-19, Development of COVID-19 tests, DiaSorin

For instance, in November 2020, ICMR introduced an ambulatory covid-19 RT-PCR lab at its facility.

Key Points: 
  • For instance, in November 2020, ICMR introduced an ambulatory covid-19 RT-PCR lab at its facility.
  • The government has also announced to establish more labs to boost COVID-19 testing.\nIn 2020, the swabs COVID-19 sample kits industry segment accounted for the largest share.
  • This high share is attributed to the reliance on several approved diagnostic products on the use of nasopharyngeal swabs.
  • For instance, in November 2020, U.S.-based company AnPac Bio-Medical announced the approval of its EUA-antibody test by the FDA for Roche\'s Elecsys Anti Sars-COV-2 test.\nPlayers and organizations across the globe are developing innovative products for sample collection.

Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export Permit

Retrieved on: 
Tuesday, April 27, 2021
Health, Medicine, Nasopharyngeal swab, Respiratory therapy, COVID-19, Sampling, COVID-19 testing, Health, Medicine, Nasopharyngeal swab, Respiratory therapy, COVID-19, Sampling, COVID-19 testing

This test kit requires no blood, and only a nasopharyngeal swab is needed to collect samples.

Key Points: 
  • This test kit requires no blood, and only a nasopharyngeal swab is needed to collect samples.
  • It can also deliver the test results within 10 minutes.
  • Getting the export authorization is an important achievement in our effort to overcome the coronavirus.
  • This new test kit can let testers know whether they have the antigen before the vaccination.

Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data

Retrieved on: 
Tuesday, March 23, 2021
Medicine, Laboratory techniques, Branches of biology, Medical tests, Clinical medicine, Nasopharyngeal swab, Respiratory therapy, Rapid antigen test, Polymerase chain reaction, COVID-19 testing

"Ortho Clinical Diagnostics continues to innovate to provide them with solutionsincluding our antigen test with new performance and sensitivity data, that enable fast, high-volume testing with accurate results."

Key Points: 
  • "Ortho Clinical Diagnostics continues to innovate to provide them with solutionsincluding our antigen test with new performance and sensitivity data, that enable fast, high-volume testing with accurate results."
  • Further, the authorization allows for easier and faster sample collection.4
    Testing leaders will now be able to utilize three additional viral transport media (VTM) options.
  • The VITROS SARS-CoV-2 Antigen Test also offers a practical and cost-effective testing alternative to polymerase-chain reaction (PCR) tests, which, while highly accurate, can be expensive and require long processing times during testing surges.
  • 1 Using Nasopharyngeal Swab specimen collection.Nasal Swab specimen collection demonstrated 92.3% sensitivity at cycle thresholds values of less than 30.

Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data

Retrieved on: 
Tuesday, March 23, 2021
Medicine, Laboratory techniques, Branches of biology, Medical tests, Clinical medicine, Nasopharyngeal swab, Respiratory therapy, Rapid antigen test, Polymerase chain reaction, COVID-19 testing

"Ortho Clinical Diagnostics continues to innovate to provide them with solutionsincluding our antigen test with new performance and sensitivity data, that enable fast, high-volume testing with accurate results."

Key Points: 
  • "Ortho Clinical Diagnostics continues to innovate to provide them with solutionsincluding our antigen test with new performance and sensitivity data, that enable fast, high-volume testing with accurate results."
  • Further, the authorization allows for easier and faster sample collection.4
    Testing leaders will now be able to utilize three additional viral transport media (VTM) options.
  • The VITROS SARS-CoV-2 Antigen Test also offers a practical and cost-effective testing alternative to polymerase-chain reaction (PCR) tests, which, while highly accurate, can be expensive and require long processing times during testing surges.
  • 1 Using Nasopharyngeal Swab specimen collection.Nasal Swab specimen collection demonstrated 92.3% sensitivity at cycle thresholds values of less than 30.